This morning Merck (NYSE:MRK) released their third quarter results and not unexpectedly sales of Januvia and Janumet continue to accelerate. In the third quarter sales of the two drugs reached $204 million and appear on track to reach blockbuster status next year. Still the only DPP4 on the market Merck continues to enjoy exclusive status in this new category and is building what looks like an insurmountable lead against any future competitors.
About the only thing standing in Januvia’s path to blockbuster status would be reports of more serious adverse events. As noted last week Merck has changed the Januvia’s label to reflect recent disclosures of adverse events related to a serious skin disease. Baring any further disclosures and given the lack of any serious competition Januvia has given Merck the home run it desperately needed.